Atlas Trials

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

Clinical trial NCT06290817 · UNKNOWN

Trial details

NCT number
NCT06290817
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2023-03-30
Primary completion
2025-03-30
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.